Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 4/20 | 0.71 |
| ▸ | MAP1LC3B | Q9GZQ8 | 7/20 | 0.59 |
| ▸ | CRBN | Q96SW2 | 6/20 | 0.56 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.52 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.52 |
| ▸ | BRD4 | O60885 | 2/20 | 0.52 |
| ▸ | TNF | P01375 | 1/20 | 0.52 |
| ▸ | IL1B | P01584 | 1/20 | 0.52 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.52 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.52 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | AXL | P30530 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28989000 | 0.99 | STAT3 (0.69) | STAT3MAP1LC3BCRBNIKZF3IKZF1 | |
| SCHEMBL22773798 | 0.92 | STAT3 (0.67) | STAT3MAP1LC3BCRBNIKZF3IKZF1 | |
| SCHEMBL20933049 | 0.92 | STAT3 (0.67) | STAT3MAP1LC3BCRBNIKZF3IKZF1 | |
| SCHEMBL30189570 | 0.92 | STAT3 (0.67) | STAT3MAP1LC3BCRBNIKZF3IKZF1 | |
| SCHEMBL22788954 | 0.92 | STAT3 (0.67) | STAT3MAP1LC3BCRBNIKZF3IKZF1 | |
| SCHEMBL22789078 | 0.92 | STAT3 (0.67) | STAT3MAP1LC3BCRBNIKZF3IKZF1 | |
| SCHEMBL30996464 | 0.91 | STAT3 (0.66) | STAT3MAP1LC3BCRBNIKZF3IKZF1 | |
| SCHEMBL21332800 | 0.91 | STAT3 (0.66) | STAT3MAP1LC3BCRBNIKZF3IKZF1 | |
| SCHEMBL31113626 | 0.91 | STAT3 (0.68) | STAT3MAP1LC3BCRBNIKZF3IKZF1 | |
| SCHEMBL21294451 | 0.91 | STAT3 (0.66) | STAT3MAP1LC3BCRBNIKZF3IKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11723980-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230150974-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230106066-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| US-20230078961-A1 | HMG-CoA Reductase Degradation Inducing Compound | UPPTHERA INC. (KR) | 2023-03-16 | — | — | US | disclosed |
| EP-4132529-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| US-11318205-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| WO-2021201577-A1 | HMG-COA REDUCTASE DEGRADATION INDUCING COMPOUND | UPPTHERA (KR) | 2021-10-07 | — | — | WO | disclosed |
| US-10874743-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| EP-3731869-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874743-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | STAT3 145/4885MAP1LC3B 1569/4885CRBN 187/4885 |
| US-20230106066-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | STAT3 145/4885MAP1LC3B 1569/4885CRBN 187/4885 |
| US-20230150974-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | STAT3 3892/4885MAP1LC3B 346/4885CRBN 179/4885 |
| US-11723980-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | STAT3 145/4885MAP1LC3B 1569/4885CRBN 187/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | STAT3 145/4885MAP1LC3B 1569/4885CRBN 187/4885 |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | STAT3 145/4885MAP1LC3B 1569/4885CRBN 187/4885 |
| US-20230078961-A1 | HMG-CoA Reductase Degradation Inducing Compound | HMGCR, HMGB2, LDLR | STAT3 4250/4885MAP1LC3B 909/4885CRBN 1616/4885 |
| US-11318205-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | STAT3 145/4885MAP1LC3B 1569/4885CRBN 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.